15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia

Female Predisposition to Autoimmunity & Immunologic Sex Dimorphism

Approximately 80% of all individuals diagnosed with autoimmune disorders are female. In conditions such as systemic lupus erythematosus (SLE) and Sjögren syndrome, the female-to-male ratio reaches 9:1, while in Hashimoto thyroiditis it is 8:1, and in rheumatoid arthritis (RA) it is 3:1. This female vulnerability results from hormonal, genetic, and reproductive factors:

• Estrogen Modulation of Humoral Immunity: Estrogen (17-beta-estradiol) promotes B-cell survival by downregulating apoptosis, enhances immunoglobulin and autoantibody synthesis, stimulates polyclonal B-cell activation, and elevates immunostimulatory prolactin. Conversely, androgens and high-dose progesterone exert immunosuppressive effects, dampening cellular immunity and downregulating pro-inflammatory cytokines.
• X-Chromosome Inactivation & Gene Dosage: The X chromosome encodes a dense cluster of immune-related genes, including TLR7 (nucleic acid sensing), CD40L, FOXP3, and IL2RG. While one X chromosome is inactivated in female somatic cells, roughly 15% to 25% of X-linked genes escape inactivation. Overexpression or gene dosage of these escaped loci lowers the activation threshold for autoreactive lymphocytes in females.
• Fetal Microchimerism: Transplacental cellular trafficking allows allogeneic fetal cells to engraft in maternal tissues for decades post-pregnancy, potentially triggering graft-versus-host-like autoimmune reactions in genetically predisposed women.

---

Systemic Lupus Erythematosus (SLE): Diagnostic Criteria & Clinical Hallmarks

SLE is a systemic autoimmune disease characterized by polyclonal B-cell hyperreactivity, autoantibody production, and widespread immune-complex tissue deposition.

Epidemiology & ACR/EULAR Diagnostic Criteria

SLE predominantly affects women during peak reproductive years (ages 15 to 44), with a female-to-male ratio of 9:1 and increased prevalence and severity in Black, Hispanic, and Asian women.

• Entry Criterion: Antinuclear antibody (ANA) titer ≥1:80 on HEp-2 cells by indirect immunofluorescence (sensitivity >95%; a negative ANA makes SLE highly improbable).
• Confirmatory Serologies:
  • Anti-Double-Stranded DNA (anti-dsDNA): Highly specific (~95%); titers fluctuate dynamically with disease activity and correlate strongly with active lupus nephritis.
  • Anti-Smith (anti-Sm): Highly specific (~99%), though present in only 20% to 30% of patients; does not correlate with activity.
  • Complement Levels: Low serum C3 and C4 indicate immune-complex consumption during flares.
  • Antiphospholipid Antibodies: Present in 30% to 40% of SLE patients, conferring secondary Antiphospholipid Syndrome risks.

Multisystem Clinical Manifestations

• Cutaneous: Malar "butterfly" rash (erythema over the bridge of the nose and malar eminences that characteristically SPARES the nasolabial folds, differentiating it from rosacea); photosensitivity; discoid lesions (scarring plaques with follicular plugging); painless oral or nasopharyngeal ulcers; non-scarring alopecia.
• Musculoskeletal: Migratory, symmetric, non-erosive polyarthritis. Unlike RA, SLE arthritis does not produce bony erosions on radiographs (Jaccoud arthropathy represents reversible tendon laxity).
• Serositis: Pleuritis and pericarditis.
• Lupus Nephritis: Occurs in up to 50% of patients. Manifests as proteinuria (>0.5 g/24 hours), active urinary sediment (RBC casts, cellular casts), and rising creatinine; renal biopsy is the gold standard for ISN/RPS histologic classification (Classes I to VI; Class III focal and Class IV diffuse proliferative carry the highest risk of renal failure).
• Hematologic & Neuropsychiatric: Autoimmune hemolytic anemia, leukopenia (<4,000/mcL), lymphopenia (<1,000/mcL), immune thrombocytopenia (<100,000/mcL), seizures, psychosis, and cerebritis.

---

Reproductive Health, Preconception Planning & Gestational Risks in SLE

Preconception Remission Requirement

Pregnancy should be planned strictly after SLE disease activity has been quiescent for at least 6 consecutive months on pregnancy-compatible medications, with stable renal function (creatinine <1.2 mg/dL, proteinuria <0.5 g/day, and controlled blood pressure). Conceiving during active lupus triggers maternal flares in >50% and dramatically elevates fetal loss.

Maternal Gestational Complications

• Lupus Flares vs. Preeclampsia:
  • Lupus Renal Flare: Rising anti-dsDNA titers, falling C3/C4 complement levels, active urine sediment with RBC casts, and systemic lupus features.
  • Preeclampsia: Normal complement levels, stable anti-dsDNA, hyperuricemia, elevated liver transaminases, and thrombocytopenia without active urinary sediment.
• Preeclampsia Prophylaxis: SLE confers a 3- to 4-fold baseline increase in preeclampsia risk; all gravidas with SLE should initiate low-dose aspirin (81 to 162 mg daily) at 12 weeks gestation.
• Contraception: Estrogen-containing methods are contraindicated in women with positive antiphospholipid antibodies (US MEC Category 4); progestin-only options (IUD, implant, DMPA, POPs) and copper IUD are safe.

---

Neonatal Lupus Erythematosus & Congenital Complete Heart Block

Neonatal lupus is caused by transplacental transmission of maternal IgG autoantibodies, specifically anti-Ro/SSA and anti-La/SSB antibodies:

• Congenital Heart Block: Maternal anti-Ro/SSA antibodies cross the placenta starting at 16 weeks, binding to fetal cardiomyocytes and the atrioventricular (AV) node. This provokes complement activation, myocarditis, and permanent dystrophic calcification and fibrosis of the AV node, resulting in congenital complete (third-degree) heart block.
• Surveillance: Occurs in ~2% of anti-Ro/SSA-positive mothers, rising to 18% to 20% if a prior infant was affected. Serial fetal echocardiography every 1 to 2 weeks from 16 to 26 weeks gestation is mandatory to detect PR interval prolongation or fetal bradycardia (<100 bpm).
• Cutaneous Neonatal Lupus: Transient annular erythematous plaques (periorbital "raccoon eyes") and transaminitis resolve by 6 months of age as maternal IgG clears from infant circulation.

---

Gestational Pharmacotherapy Safety in SLE: The Hydroxychloroquine Imperative

---

Antiphospholipid Syndrome (APS) in Women & Pregnancy

Antiphospholipid Syndrome is a systemic autoimmune thrombophilia characterized by vascular thrombosis and/or adverse pregnancy outcomes with persistent antiphospholipid antibodies.

Sydney / Revised Sapporo Diagnostic Criteria

Requires at least one clinical criterion AND at least one laboratory criterion:

• Clinical Criteria:
  1. Vascular Thrombosis: ≥1 confirmed episode of arterial, venous, or microvascular thrombosis.
  2. Obstetric Morbidity:
     • ≥3 consecutive unexplained spontaneous abortions prior to 10 weeks gestation; OR
     • ≥1 unexplained fetal demise of a morphologically normal fetus at or beyond 10 weeks gestation; OR
     • ≥1 premature birth of a normal infant prior to 34 weeks gestation due to severe preeclampsia, eclampsia, or severe placental insufficiency.
• Laboratory Criteria (confirmed on ≥2 occasions ≥12 weeks apart):
  1. Lupus Anticoagulant (LA).
  2. Anticardiolipin Antibodies (aCL): Medium-high titer IgG or IgM (>40 GPL/MPL units, or >99th percentile).
  3. Anti-Beta-2 Glycoprotein I Antibodies: IgG or IgM >99th percentile.

Gestational Antithrombotic Protocols

• Obstetric APS (Pregnancy Morbidity without Prior Thrombosis): Initiate low-dose aspirin (81 to 162 mg daily) preconception, and add prophylactic-dose low-molecular-weight heparin (LMWH, e.g., enoxaparin 40 mg SQ daily) upon confirmation of intrauterine pregnancy. Continue through pregnancy and for 6 weeks postpartum.
• Thrombotic APS (History of Prior Thrombosis): Low-dose aspirin plus therapeutic-dose LMWH (e.g., enoxaparin 1 mg/kg SQ every 12 hours) throughout gestation and postpartum.
• Contraindicated Anticoagulants: Warfarin (warfarin embryopathy: nasal hypoplasia, stippled epiphyses) and DOACs (cross placenta) are strictly contraindicated in pregnancy.

---

Rheumatoid Arthritis & Fibromyalgia in Women

Rheumatoid Arthritis (RA)

• Presentation: Symmetrical polyarthritis affecting the small joints of the hands and feet (MCP, PIP, MTP; characteristically SPARING the DIP joints and thoracolumbar spine). Cardinal feature: morning joint stiffness lasting >1 hour improving with activity; synovial thickening and boggy effusions.
• Serology: Rheumatoid Factor (RF; sensitivity 70%–80%) and Anti-CCP antibodies (specificity >95%–98%); elevated ESR and CRP.
• Gestational Course: Roughly 60% to 70% of women experience spontaneous improvement or remission during pregnancy, followed by a sharp postpartum flare in up to 90% within 3 to 6 months after delivery. Pregnancy-compatible DMARDs include sulfasalazine, hydroxychloroquine, and certolizumab pegol.

Fibromyalgia

• Pathophysiology: Chronic, non-inflammatory widespread musculoskeletal pain syndrome driven by central sensitization (augmented central nociceptive processing producing hyperalgesia and allodynia). Female-to-male ratio is 8:1, onset 30 to 55 years.
• Clinical Hallmarks: Diffuse bilateral pain above and below the waist for ≥3 months, profound fatigue, non-restorative sleep, cognitive dysfunction ("fibro fog"), and somatic comorbidities (IBS, tension headaches). The 2016 ACR criteria use the widespread pain index and symptom severity scale instead of a tender-point count; the exam shows diffuse tenderness WITHOUT joint swelling, warmth, or synovitis. Inflammatory markers (ESR, CRP) and muscle enzymes (CK) are completely normal.
• Multimodal Management: Graded low-impact aerobic exercise, cognitive behavioral therapy (CBT), sleep hygiene, and FDA-approved pharmacotherapy: SNRIs (duloxetine 30–60 mg daily, milnacipran) or pregabalin (150–450 mg daily). Opioids and systemic corticosteroids are strictly avoided due to lack of efficacy and hyperalgesia/dependence risks.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)

• Diagnosis (National Academy of Medicine, 2015): At least 6 months of substantially reduced activity with profound fatigue, post-exertional malaise, and unrefreshing sleep, plus either cognitive impairment or orthostatic intolerance. It is roughly three times more common in women.
• Exclude mimics: CBC (anemia), TSH, metabolic panel, celiac serology, sleep apnea, depression, and medication effects.
• Management: Activity pacing within the patient's energy envelope (CDC no longer recommends graded exercise therapy), sleep hygiene, treatment of orthostatic symptoms and pain, and supportive counseling. Fibromyalgia and ME/CFS often coexist.